Breaking News
July 19, 2018 - Five tips for men seeking plastic surgery
July 19, 2018 - Researchers discover the reasons why some people get dizzy when hearing certain sounds
July 19, 2018 - Melanoma could soon be detected using a blood test
July 19, 2018 - Exposure to bright light may have big impact on sleep-related behavior in children
July 19, 2018 - Deleting single gene in gut bacteria affects metabolism, reduces weight gain in mice
July 19, 2018 - New proteomics studies help gain more insights into Alzheimer’s, cancer and listeriosis
July 19, 2018 - Study finds major discrepancies in prescription drug labeling pregnancy information across four countries
July 19, 2018 - Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
July 19, 2018 - Watching the immune system in action reveals what happens when things goes wrong
July 19, 2018 - Increasing blood sugar levels improves memory and performance in older adults
July 19, 2018 - Connection between self-regulation and obesity appears to be different for girls and boys
July 19, 2018 - Researchers develop new, less destructive method for whitening teeth
July 19, 2018 - Revving up innate control of viral infection requires a three-cell ignition
July 19, 2018 - Inaccurate direct-to-consumer raw genetic data can harm patients, new research suggests
July 19, 2018 - Weight loss surgery is effective under the right situations
July 19, 2018 - BioTek awarded patent for autofocus feature on microplate reader
July 19, 2018 - Low-carb diets reduce stiffness of arteries in women and promote weight loss in men
July 19, 2018 - New review examines cannabinoids’ potential for direct treatment of cancer
July 19, 2018 - Allergic responses may help protect the skin against cancer, research suggests
July 19, 2018 - Inappropriate Prescribing of Abx High in Urgent Care Centers
July 19, 2018 - Many at risk for HIV despite lifesaving pill
July 19, 2018 - Tips for doctors and parents on the harms of marijuana use for teens
July 18, 2018 - Researchers detect presence of IgE antibodies after kidney transplantation
July 18, 2018 - New technique allows researchers to create large scale, personalized bone grafts
July 18, 2018 - Smoking May Boost Atrial Fibrillation Risk
July 18, 2018 - Genome editing method targets AIDS virus
July 18, 2018 - These things matter: Medical complications are not inevitable, a physician writes
July 18, 2018 - Cognitive functions often wilt as water departs the body, shows study
July 18, 2018 - Origins of bread found 14,400 years ago in Jordan
July 18, 2018 - Low-dose ketamine found to be as effective as opioids for treating acute pain
July 18, 2018 - Novel bioengineering technique could help repair bone defects
July 18, 2018 - Researchers identify new potential target protein for colon cancer
July 18, 2018 - Air pollution contributes significantly to diabetes globally
July 18, 2018 - Cell membrane’s importance offers new strategy to fight infections
July 18, 2018 - Researchers identify key protein involved in irregular brain cell activity
July 18, 2018 - 3D modeling of drug resistance could lead to more effective cancer treatment
July 18, 2018 - Hunger hormones could be key to new treatments for drug, alcohol addiction
July 18, 2018 - Nitrate-cured meats may contribute to mania, study finds
July 18, 2018 - Why men may recover more quickly from influenza infections than women
July 18, 2018 - Study finds discharge against medical advice as predictor of readmissions in heart attack patients
July 18, 2018 - KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
July 18, 2018 - Self-control and obesity: Gender matters in children
July 18, 2018 - Bioengineers, diabetes researchers convene to discuss future concepts for precision medicine
July 18, 2018 - New findings support more conservative use of ED neuroimaging for non-index seizures
July 18, 2018 - Practicing yoga benefits pregnant women, study suggests
July 18, 2018 - New strategy may lead to more accurate breast cancer diagnoses
July 18, 2018 - FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
July 18, 2018 - New guide helps hospitals pick right partner to handle hospitalist services
July 18, 2018 - Deep data dive helps predict cerebral palsy
July 18, 2018 - Stricter firearm legislation associated with reduced murder and suicide rates
July 18, 2018 - Physical and sexual abuse in childhood associated with endometriosis risk
July 18, 2018 - Omega 3 supplements do not reduce risk of heart disease, stroke or death
July 18, 2018 - GSA’s new publication provides support for safe use of OTC analgesics by older adults
July 18, 2018 - Researchers receive grant from U.S. Department of Education to study children with HFASD
July 18, 2018 - Early childhood adversity increases sensitivity of the body’s immune response to cocaine
July 18, 2018 - Parental incarceration affects health behaviors of children in adulthood
July 18, 2018 - Researchers find that yellow fever and Asian tiger mosquitoes can carry new virus
July 18, 2018 - Two Regimens Fail to Stop Declines in β-Cell Function
July 18, 2018 - Researchers apply computing power to track the spread of cancer
July 18, 2018 - Olfactory receptors play pathophysiological role in all organs than merely smell perception
July 18, 2018 - Fish consumption associated with lower risk of early death
July 18, 2018 - MR Solutions’ 7T MRI imaging system installed at University of Hawaii
July 18, 2018 - Humorous ads screened around World Cup game achieve higher biometric response than sporty ads
July 18, 2018 - New study demonstrates little effect of hormone therapy on artery thickness
July 18, 2018 - A 3-Pronged Plan to Cut Type 2 Diabetes Risk
July 18, 2018 - New clues to sepsis may speed diagnosis
July 18, 2018 - Stars of Stanford Medicine: Improving cardiovascular health in Africa and beyond
July 18, 2018 - Heart attack risk continues to increase among pregnant women, study finds
July 18, 2018 - Few tips to help avoid sunburns in summer
July 18, 2018 - High-fat diet and systemic inflammation contribute to progression of prostate cancer
July 18, 2018 - Researchers develop 3D map of gene interactions that play key role in heart disease
July 18, 2018 - Conservative management of lung subsolid nodules reduces overtreatment and unnecessary surgery
July 18, 2018 - Report warns of dog illness that can spread to owners
July 18, 2018 - A winning essayist’s tips for keeping track of scientific facts
July 18, 2018 - Researchers seek to understand role of APOE mutation in Alzheimer’s disease
July 18, 2018 - Animal studies reveal brain changes responsible for appetite effects of cannabis
July 18, 2018 - New ZEISS ZEN Intellesis machine allows segmentation of correlative microscopy
July 18, 2018 - Study findings highlight importance of early detection of SMA through newborn screening
July 18, 2018 - Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of Pixuvri (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
July 18, 2018 - Diabetes researchers find switch for fatty liver disease
‘Soft’ Chemo Plus Targeted Therapy Works in HER2 Breast Cancer

‘Soft’ Chemo Plus Targeted Therapy Works in HER2 Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized trial found that the addition of the somewhat “gentle” chemotherapy metronomic oral cyclophosphamide to pertuzumab and trastuzumab increased progression-free survival among older women with HER-2 positive breast cancer.
  • Be aware that these patients were all either over 70 years old, or over 60 with certain functional limitations.

A combination of “soft” chemotherapy and anti-HER2 therapy is effective in older patients with HER2-positive metastatic breast cancer and comes with an acceptable safety profile, investigators have found.

Specifically, they determined that the use of trastuzumab and pertuzumab with the “softer” chemotherapy metronomic oral cyclophosphamide provided patients with seven months longer progression-free survival compared to patients who were treated with trastuzumab and pertuzumab alone.

The study, led by Hans Wildiers, MD, PhD, University Hospitals Leuven, in Belgium, was published in The Lancet Oncology.

As pointed out by Wildiers and his colleagues, while HER2-positive metastatic breast cancer is particularly aggressive if left untreated, advances in HER2-directed drug development have resulted in improvements in outcomes.

For example, the phase 3 CLEOPATRA Trial showed that the addition of trastuzumab to pertuzumab and the chemotherapy drug docetaxel significantly improved progression-free survival, as well as overall survival.

While docetaxel combined with trastuzumab and pertuzumab has been shown to be effective in younger patients with HER2 positive metastatic breast cancer, it can be significantly toxic and affect quality of life, particularly in older patients.

The question Wildiers and his colleagues wanted to address was whether the introduction of HER2–directed therapies makes it possible to treat older HER2-positive metastatic breast cancer patients with HER2-targeted regimens and without classical therapies.

They pointed out that the dual blockade of HER2 with trastuzumab and pertuzumab has shown substantial anti-tumor activity. At the same time metronomic chemotherapy with oral cyclophosphamide has shown antitumor activity with minimal toxicity, making it more suitable for older patients.

“Given the need to develop new treatment strategies with limited toxicity for older patients with breast cancer, we aimed to examine the safety and activity of dual anti-HER2 treatment with or without metronomic chemotherapy in this population,” Wildiers and his colleagues wrote.

In this open-label, randomized, phase II trial, 80 patients were randomly assigned to receive trastuzumab and pertuzumab (TP) or TP plus metronomic oral cyclophosphamide (TPM). The patients were 70 years of age or older, or 60 years or older if they presented with certain functional limitations. The median age of the study participants was 76.7 years.

Wildiers and his colleagues found that estimated progression-free survival at 6 months was 46.2% (95% CI, 30.2-60.7) with TP alone compared to 73.4% (95% CI, 56.6-84.6) with TPM. At a median follow-up of 20.7 months, the median progression-free survival was 5.6 months (95% CI, 3.6-16.8) in the TP group versus 12.7 months (95% CI, 6.7-24.8) in the TPM group.

The most frequent grade 3-4 adverse events included hypertension (in 6 [15%] of 39 patients in the trastuzumab and pertuzumab group versus 5 [12%] of 41 in the trastuzumab and pertuzumab plus metronomic oral cyclophosphamide group), diarrhea (4 [10%] versus 5 [12%]), dyspnea (2 [5%] versus 4 [10%]), fatigue (3 [8%] versus 2 [5%]), pain (2 [5%] versus 2 [5%]), and a thromboembolic event (0 [0%] versus 4 [10%]).

In a press release Wildiers called the results “encouraging,” since he and his colleagues were able to show that the use of gentle therapy among older, frail patients could delay tumor growth while delaying or even avoiding the use of more toxic chemotherapy.

“In this age group, maintenance of [quality of life] and the avoidance of toxic side-effects may be just as important as survival,” he said.

“We believe that there is a strong case for carrying out trials designed specifically for older people,” Wildiers added. “However, financial support for such trials is very difficult to find. Additionally, older patients are far less likely to receive standard chemotherapy, and are also unlikely to be included in a randomized trial where there is a risk that they will receive a treatment with high toxicity.”

In a commentary accompanying the study, Charles E. Geyer, MD, Massey Cancer Center, Virginia Commonwealth University, also noted that while clinical trials are a prerequisite for establishing new treatment standards, “eligibility criteria generally restrict participation to fit populations with minimal comorbidities,” which, in turn, results in the underrepresentation in clinical trials of older patients with functional limitations.

Thus, Wildiers and his colleagues “are to be congratulated on their demonstration of a framework for clinical trials in older, more frail patients with HER-positive-metastatic breast cancer,” wrote Geyer.

Wildiers reports research grants from Roche and personal fees towards his institute from Roche, Amgen, Novartis, Pfizer, Puma, and Celldex. Geyer has received personal fees from Myriad and Heron Therapeutics for advisory board participation and travel support from AstraZeneca, Genentech, and Macrogenics, outside the submitted work.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-12-02T00:00:00-0500

last updated

Tagged with:

About author

Related Articles